首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1544183

血液篩檢市場規模、佔有率、成長分析：按產品和服務、按技術、按最終用戶、按地區 - 行業預測，2024-2031 年

Blood Screening Market Size, Share, Growth Analysis, By Product Type (Reagents & Kits, Instruments), By Technology (Nucleic Acid Test (NAT), Rapid Tests), By End User (Hospitals & Clinics, Diagnostic Centers), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月24日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計2022年全球血液篩檢市場規模將達30.4億美元，從2023年的33億美元增加至2031年的63.3億美元，複合年成長率預計將成長8.50%。

血液篩檢自動化分子平台正在推動市場的顯著成長，業界領先的公司紛紛採用這項技術。促成這一市場擴張的主要因素包括捐血和捐血數量的增加、血液安全意識的提高、感染疾病發病率的上升以及政府的各種措施。該市場還受益於大型手術的頻率，尤其是輸血，這對於治療兒童貧血、創傷和先天性血液疾病至關重要。根據我們的分析，全球每年進行超過 2.34 億例大型手術，需要頻繁輸血。全球約有1.185億次捐血，其中40%來自高所得國家，佔全球捐血的16%。不同收入水準的捐血分佈不同，高所得國家佔31.5%，中高收入國家佔15.9%，中低收入國家佔6.8%，低收入國家佔5.0%。在主要產業參與者之間的策略夥伴關係的推動下，診斷測試領域有望實現顯著成長。這些合作夥伴關係預計將增加先進診斷測試的可用性。例如，2023年3月，TruDiagnostic與專門從事NAD診斷的芬蘭公司NADMED合作，在美國推出創新的NAD+血液診斷測試。此次合作凸顯了診斷能力擴大和市場成長的不斷成長趨勢。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Abbott Laboratories（USA）
Becton, Dickinson and Company（USA）
Bio-Rad Laboratories, Inc.（USA）
bioMerieux SA（France）
F. Hoffmann-La Roche Ltd.（Switzerland）
Grifols, SA（Spain）
Hologic, Inc.（USA）
Immucor, Inc.（USA）
Meridian Bioscience, Inc.（USA）
Ortho Clinical Diagnostics（USA）
Quotient Limited（UK）
Siemens Healthineers AG（Germany）
Sysmex Corporation（Japan）
Thermo Fisher Scientific Inc.（USA）
Danaher Corporation（USA）
Grifols Diagnostic Solutions Inc.（USA）
Haemonetics Corporation（USA）
Luminex Corporation（USA）
Natera, Inc.（USA）
Novartis International AG（Switzerland）
PerkinElmer, Inc.（USA）
Promega Corporation（USA）

簡介目錄

Product Code: SQMIG35J2044

Global Blood Screening Market size was valued at USD 3.04 Billion in 2022 and is poised to grow from USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

Automated molecular platforms for blood screening are driving significant growth in the market, as leading industry players adopt this technology. Key factors fueling this expansion include the increasing number of blood donations and donors, heightened awareness of blood safety, the rising incidence of infectious diseases, and various government initiatives. The market is also benefiting from the frequency of blood transfusions, which are essential in major surgeries, particularly in managing childhood anemia, trauma, and congenital blood disorders. Based on our analysis, over 234 million major surgeries are conducted globally each year, necessitating frequent blood transfusions. Our study also reveals that approximately 118.5 million blood donations occur worldwide, with 40% coming from high-income countries, which contribute to 16% of global donations. The distribution of donations varies by income level, with high-income countries accounting for 31.5% of donations, upper-middle-income countries 15.9%, lower-middle-income countries 6.8%, and low-income countries 5.0%. The diagnostic testing landscape is poised for substantial growth, driven by strategic partnerships among key industry players. These collaborations are expected to enhance the availability of advanced diagnostic tests. For instance, in March 2023, TruDiagnostic partnered with NADMED, a Finnish company specializing in NAD diagnostics, to launch an innovative NAD+ blood diagnostic test in the U.S. This partnership highlights the increasing trend towards expanding diagnostic capabilities and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Blood Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Blood Screening Market Segmental Analysis

Global Blood Screening Market is segmented based on product type, technology, end users, and region. Based on product & service, the market is segmented into Reagents & Kits [NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents & Kits], Instruments [Rental Purchase, Outright Purchase], Software & Services. Based on technology, the market is segmented into Nucleic Acid Test (NAT) [Transcription-mediated Amplification (TMA), Real-time Polymerase Chain Reaction (RT-PCR)], Serology/Immunoassay [Chemiluminescent Immunoassays (CLIA), Fluorescent Immunoassays (FIA), Colorimetric Immunoassays/ELISA (CI/ELISA)], Rapid Tests, Western Blot Assays, Next-generation Sequencing (NGS). Based on end user, the market is segmented into hospitals & clinics, diagnostic centres, and blood banks. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Blood Screening Market

Awareness among healthcare professionals and patients regarding the risks of blood transfusions, such as the transmission of infectious diseases, is increasing. This heightened awareness is driving a greater demand for blood screening products that ensure the safety of blood and blood products. Additionally, the growing prevalence of blood-related disorders and the rising need for blood and blood products for various medical procedures, including transfusions and surgeries, are contributing to the expansion of the blood screening market. This demand underscores the need for effective screening solutions to enhance safety and manage the risks associated with blood transfusions.

Restraints in the Global Blood Screening Market

The shortage of phlebotomists, laboratory technicians, and other skilled professionals could hinder the widespread adoption of blood screening products. Healthcare organizations and blood banks may face difficulties in finding qualified personnel to operate the equipment and conduct the tests, potentially limiting their ability to implement blood screening programs effectively. This workforce gap poses a significant challenge to expanding the use of blood screening technologies and ensuring their widespread availability.

Market Trends of the Global Blood Screening Market

The rising demand for plasma-derived products, including immunoglobulins and clotting factors, is significantly boosting the need for blood screening products that ensure the safety of these essential therapies. As plasma-derived treatments continue to expand into new therapeutic areas, the demand for reliable blood screening solutions is expected to grow. In the United States, the increasing prevalence of chronic diseases such as cancer, diabetes, and thyroid disorders is anticipated to further drive market growth. The American Cancer Society's "Cancer Facts and Figures 2023" report projects around 1.9 million new cancer cases for the year, with prostate cancer being the most common, followed by lung and female breast cancers. Similarly, data from the Government of Canada reported 233,900 new cancer diagnoses, with prostate cancer remaining the most prevalent. This rising cancer burden is likely to boost the demand for blood testing services, supporting market expansion throughout the forecast period.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Patent Analysis
Pricing Analysis
Trade Analysis
Consumer And Buying Criteria
Regulatory Analysis
Technology Analysis
Case study Analysis

Global Blood Screening Market by Product and services

Market Overview
Reagents and kits
- NAT reagents and kits
- Elisa reagents and kits
- Other Reagents and kits
Instruments
- Rental purchase
- Outright purchase
Software and services

Global Blood Screening Market by Technology

Market Overview
Nucleic acid test
- Transcription-mediated Amplification
- Real-time PCR
Serology/Immunoassay
- Chemiluminescent Immunoassays
- Fluorescent Immunoassays
- Colorimetric Immunoassays/ELISA
Rapid Tests
Western Blot Assays
Next-generation Sequencing

Global Blood Screening Market by End-user

Market Overview
Hospitals & Clinics
Diagnostic centers
Blood Banks

Global Blood Screening Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immucor, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ortho Clinical Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quotient Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols Diagnostic Solutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luminex Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments